Repertoire Genesis Overview

  • Founded
  • 2014

Founded
  • Status
  • Acquired/​Merged

  • Employees
  • 20

Employees
  • Latest Deal Type
  • M&A

Repertoire Genesis General Information

Description

Repertoire Genesis Inc is a biotechnology company. It supports the development of new diagnostic methods/therapies based on immune diversity analysis.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Parent Company
Primary Office
  • Nihonbashi Life Science Building 2 703
  • 3-11-5 Nihonbashihoncho, Chuo-ku
  • Tokyo, 103-0023
  • Japan
+81 000-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Repertoire Genesis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 31-May-2022 000.00 Completed Generating Revenue
6. IPO 09-Mar-2022 00.000 000.00 Cancelled Generating Revenue
5. Later Stage VC 26-Feb-2020 00000 000.00 Completed Generating Revenue
4. Later Stage VC 30-Sep-2019 00.000 000.00 Completed Generating Revenue
3. Later Stage VC (Series C) 01-Aug-2017 00.000 00.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 27-Jul-2016 $4.81M $6.58M 000.00 Completed Product Development
1. Early Stage VC (Series A) 21-Nov-2014 $1.76M $1.76M 00.000 Completed Product Development
To view Repertoire Genesis’s complete valuation and funding history, request access »

Repertoire Genesis Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 000 000000.00 000000.00 00 000000.00 0.000
Series B 000 00000.00 00000.00 00 00000.00 00.000
Series A 400 $4455.76 $4455.76 1x $4455.76 21.98%
To view Repertoire Genesis’s complete cap table history, request access »

Repertoire Genesis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Repertoire Genesis Inc is a biotechnology company. It supports the development of new diagnostic methods/therapies based
Other Healthcare Technology Systems
Tokyo, Japan
20 As of 2022
000.00
000000&0 000.00

000000

velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, s
0000000000000
Shanghai, China
000 As of 0000
00000
0.00 0000-00-00
00000000 00000

00 000

r incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ul
0000000000000
Shanghai, China
000 As of 0000
00000
0.000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Repertoire Genesis Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CARsgen Therapeutics Formerly VC-backed Shanghai, China 000 00000 00000000 00000
00 000000000000 Formerly VC-backed Shanghai, China 000 00000 00000000 00000
You’re viewing 2 of 2 competitors. Get the full list »

Repertoire Genesis Patents

Repertoire Genesis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4060038-A1 Method for introducing antigen-specific receptor gene into t cell genome using cyclic dna Pending 14-Nov-2019 0000000000
JP-WO2020040302-A1 Method for analyzing functional subunit pair genes of t cell receptor and b cell receptor Active 24-Aug-2018 0000000000
EP-3842550-A4 Method for analyzing functional subunit pair gene of t cell receptor and b cell receptor Pending 24-Aug-2018 000000000 0
EP-3842550-A1 Method for analyzing functional subunit pair gene of t cell receptor and b cell receptor Pending 24-Aug-2018 0000000000
US-20210301324-A1 Method for analyzing functional subunit pair gene of t cell receptor and b cell receptor Pending 24-Aug-2018 C12Q1/6881
To view Repertoire Genesis’s complete patent history, request access »

Repertoire Genesis Executive Team (6)

Name Title Board Seat Contact Info
Mitsuo Ichikawa President, Chief Operating Officer, Co-Chief Executive Officer and Board Member
Ryuji Suzuki MD Co-Chief Executive Officer & Chairman
Tetsuya Maruyama Chief Financial Officer & Board Member
Noriaki Sakamoto Auditor
You’re viewing 4 of 6 executive team members. Get the full list »

Repertoire Genesis Board Members (8)

Name Representing Role Since
Osamu Arai Self Board Member 000 0000
Ryuji Suzuki MD Repertoire Genesis Co-Chief Executive Officer & Chairman 000 0000
Tetsuya Maruyama Repertoire Genesis Chief Financial Officer & Board Member 000 0000
You’re viewing 3 of 8 board members. Get the full list »

Repertoire Genesis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Repertoire Genesis Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Beyond Next Ventures Venture Capital Minority 000 0000 000000 0
The University of Tokyo Edge Capital Venture Capital Minority 000 0000 000000 0
Zenyaku Kogyo Corporation Minority 000 0000 000000 0
To view Repertoire Genesis’s complete investors history, request access »